Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
39
PMCUF Quote, Financials, Valuation and Earnings
Last price:
$155.61
Seasonality move
:
15.01%
Day range:
$157.39 - $172.58
52-week range:
$100.45 - $218.25
Dividend yield:
0%
P/E ratio:
221.86x
P/S ratio:
119.98x
P/B ratio:
153.33x
Volume:
34
Avg. volume:
187
1-year change:
-6.04%
Market cap:
$16.5B
Revenue:
$137.9M
EPS (TTM):
$0.71
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PMCUF
Pro Medicus Ltd.
|
-- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $16.49 |
|
MESO
Mesoblast Ltd.
|
$20.3M | -- | -100% | -- | $35.00 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PMCUF
Pro Medicus Ltd.
|
$157.85 | -- | $16.5B | 221.86x | $0.16 | 0% | 119.98x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.42 | $12.00 | $62M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$1.80 | $9.50 | $262M | -- | $0.00 | 0% | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
$15.05 | $16.49 | $25.1M | -- | $0.00 | 0% | 680.02x |
|
MESO
Mesoblast Ltd.
|
$17.87 | $35.00 | $2.3B | -- | $0.00 | 0% | 125.41x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PMCUF
Pro Medicus Ltd.
|
0.82% | 3.468 | -- | 6.93x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -1.575 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.640 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 5.445 | 5.57% | 0.07x |
|
MESO
Mesoblast Ltd.
|
-- | 0.345 | -- | -- |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PMCUF
Pro Medicus Ltd.
|
-- | -- | 51.6% | 51.91% | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Pro Medicus Ltd. vs. Competitors
-
Which has Higher Returns PMCUF or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Pro Medicus Ltd.'s net margin of --. Pro Medicus Ltd.'s return on equity of 51.91% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PMCUFPro Medicus Ltd.-- -- $139.3M ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About PMCUF or ATHE?
Pro Medicus Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 250.88%. Given that Alterity Therapeutics Ltd. has higher upside potential than Pro Medicus Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Pro Medicus Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PMCUFPro Medicus Ltd.0 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is PMCUF or ATHE More Risky?
Pro Medicus Ltd. has a beta of 1.554, which suggesting that the stock is 55.35% more volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.023, suggesting its less volatile than the S&P 500 by 97.656%.
-
Which is a Better Dividend Stock PMCUF or ATHE?
Pro Medicus Ltd. has a quarterly dividend of $0.16 per share corresponding to a yield of 0%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro Medicus Ltd. pays 49.87% of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend. Pro Medicus Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PMCUF or ATHE?
Pro Medicus Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Pro Medicus Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Pro Medicus Ltd.'s price-to-earnings ratio is 221.86x while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro Medicus Ltd. is 119.98x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMCUFPro Medicus Ltd.119.98x 221.86x -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns PMCUF or IMMP?
Immutep Ltd. has a net margin of -- compared to Pro Medicus Ltd.'s net margin of --. Pro Medicus Ltd.'s return on equity of 51.91% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PMCUFPro Medicus Ltd.-- -- $139.3M IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About PMCUF or IMMP?
Pro Medicus Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 427.78%. Given that Immutep Ltd. has higher upside potential than Pro Medicus Ltd., analysts believe Immutep Ltd. is more attractive than Pro Medicus Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PMCUFPro Medicus Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is PMCUF or IMMP More Risky?
Pro Medicus Ltd. has a beta of 1.554, which suggesting that the stock is 55.35% more volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.925, suggesting its more volatile than the S&P 500 by 92.469%.
-
Which is a Better Dividend Stock PMCUF or IMMP?
Pro Medicus Ltd. has a quarterly dividend of $0.16 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro Medicus Ltd. pays 49.87% of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend. Pro Medicus Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PMCUF or IMMP?
Pro Medicus Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Pro Medicus Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Pro Medicus Ltd.'s price-to-earnings ratio is 221.86x while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro Medicus Ltd. is 119.98x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMCUFPro Medicus Ltd.119.98x 221.86x -- -- IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns PMCUF or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Pro Medicus Ltd.'s net margin of --. Pro Medicus Ltd.'s return on equity of 51.91% beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital PMCUFPro Medicus Ltd.-- -- $139.3M KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About PMCUF or KZIA?
Pro Medicus Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $16.49 which suggests that it could grow by 9.6%. Given that Kazia Therapeutics Ltd. has higher upside potential than Pro Medicus Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Pro Medicus Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PMCUFPro Medicus Ltd.0 0 0 KZIAKazia Therapeutics Ltd.0 0 0 -
Is PMCUF or KZIA More Risky?
Pro Medicus Ltd. has a beta of 1.554, which suggesting that the stock is 55.35% more volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.185%.
-
Which is a Better Dividend Stock PMCUF or KZIA?
Pro Medicus Ltd. has a quarterly dividend of $0.16 per share corresponding to a yield of 0%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro Medicus Ltd. pays 49.87% of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend. Pro Medicus Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PMCUF or KZIA?
Pro Medicus Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Pro Medicus Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Pro Medicus Ltd.'s price-to-earnings ratio is 221.86x while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro Medicus Ltd. is 119.98x versus 680.02x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMCUFPro Medicus Ltd.119.98x 221.86x -- -- KZIAKazia Therapeutics Ltd.680.02x -- -- --
-
Which has Higher Returns PMCUF or MESO?
Mesoblast Ltd. has a net margin of -- compared to Pro Medicus Ltd.'s net margin of --. Pro Medicus Ltd.'s return on equity of 51.91% beat Mesoblast Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PMCUFPro Medicus Ltd.-- -- $139.3M MESOMesoblast Ltd.-- -- -- -
What do Analysts Say About PMCUF or MESO?
Pro Medicus Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Mesoblast Ltd. has an analysts' consensus of $35.00 which suggests that it could grow by 95.86%. Given that Mesoblast Ltd. has higher upside potential than Pro Medicus Ltd., analysts believe Mesoblast Ltd. is more attractive than Pro Medicus Ltd..
Company Buy Ratings Hold Ratings Sell Ratings PMCUFPro Medicus Ltd.0 0 0 MESOMesoblast Ltd.1 0 0 -
Is PMCUF or MESO More Risky?
Pro Medicus Ltd. has a beta of 1.554, which suggesting that the stock is 55.35% more volatile than S&P 500. In comparison Mesoblast Ltd. has a beta of 2.025, suggesting its more volatile than the S&P 500 by 102.508%.
-
Which is a Better Dividend Stock PMCUF or MESO?
Pro Medicus Ltd. has a quarterly dividend of $0.16 per share corresponding to a yield of 0%. Mesoblast Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro Medicus Ltd. pays 49.87% of its earnings as a dividend. Mesoblast Ltd. pays out -- of its earnings as a dividend. Pro Medicus Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PMCUF or MESO?
Pro Medicus Ltd. quarterly revenues are --, which are smaller than Mesoblast Ltd. quarterly revenues of --. Pro Medicus Ltd.'s net income of -- is lower than Mesoblast Ltd.'s net income of --. Notably, Pro Medicus Ltd.'s price-to-earnings ratio is 221.86x while Mesoblast Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro Medicus Ltd. is 119.98x versus 125.41x for Mesoblast Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMCUFPro Medicus Ltd.119.98x 221.86x -- -- MESOMesoblast Ltd.125.41x -- -- --
-
Which has Higher Returns PMCUF or PPCB?
has a net margin of -- compared to Pro Medicus Ltd.'s net margin of --. Pro Medicus Ltd.'s return on equity of 51.91% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PMCUFPro Medicus Ltd.-- -- $139.3M PPCB-- -$0.00 -- -
What do Analysts Say About PMCUF or PPCB?
Pro Medicus Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Pro Medicus Ltd. has higher upside potential than , analysts believe Pro Medicus Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings PMCUFPro Medicus Ltd.0 0 0 PPCB0 0 0 -
Is PMCUF or PPCB More Risky?
Pro Medicus Ltd. has a beta of 1.554, which suggesting that the stock is 55.35% more volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock PMCUF or PPCB?
Pro Medicus Ltd. has a quarterly dividend of $0.16 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro Medicus Ltd. pays 49.87% of its earnings as a dividend. pays out -- of its earnings as a dividend. Pro Medicus Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PMCUF or PPCB?
Pro Medicus Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Pro Medicus Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Pro Medicus Ltd.'s price-to-earnings ratio is 221.86x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro Medicus Ltd. is 119.98x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMCUFPro Medicus Ltd.119.98x 221.86x -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 3.46% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 47.95% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 10.69% over the past day.
